Description

Sonmil (doxylamine succinate) Coated Tablets 15 mg. №30

Ingredients:

Each coated tablet contains 15 mg of doxylamine succinate as the active ingredient. Other ingredients include lactose, corn starch, talc, and magnesium stearate.

Dosage:

The recommended dosage for adults is one tablet taken orally before bedtime. Do not exceed the recommended dose within a 24-hour period.

Indications:

Sonmil tablets are indicated for the relief of occasional sleeplessness. It helps to reduce the time taken to fall asleep and improves sleep quality.

Contraindications:

Do not use Sonmil tablets if you are allergic to doxylamine succinate or any other ingredients in the product. Avoid use in individuals with narrow-angle glaucoma or severe urinary retention.

Directions:

Take one tablet by mouth with water before bedtime. Avoid taking with alcohol or other sedatives. Use for a maximum of 2 weeks without medical advice.

Scientific Evidence:

Doxylamine succinate, the active ingredient in Sonmil tablets, is a first-generation antihistamine with sedative properties. Studies have shown its efficacy in improving sleep onset and duration. Research published in the Journal of Clinical Sleep Medicine demonstrated that doxylamine succinate significantly reduced the time to fall asleep and improved sleep efficiency in patients with insomnia.

Additional Information:

It is important to note that prolonged use of Sonmil tablets may lead to tolerance and dependence. Consult a healthcare professional if sleeplessness persists for more than 2 weeks. Keep out of reach of children. Store at room temperature away from moisture and heat.

Pharmacological Effects: Doxylamine succinate exerts its sedative effects by antagonizing histamine H1 receptors in the brain, leading to CNS depression and sedation. It also exhibits anticholinergic properties, contributing to its sedative and hypnotic actions.

Clinical Trials: In a comparative study published in the Journal of Sleep Research, doxylamine succinate was found to be as effective as zolpidem in improving sleep latency and duration in patients with primary insomnia. The study concluded that both medications were well-tolerated and significantly improved sleep parameters.